In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s DrugThe agency faced criticism for approving Aduhelm for all Alzheimer’s patients. The new label recommends that the drug be given only to patients with mild symptoms.In a Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drug
'Some Hope Is Better Than Having No Hope' · The New York Times'Some Hope Is Better Than Having No Hope' · The New York Times
Controversial Alzheimer’s drug could cost US $334B—nearly half of DoD budgetDespite unproven efficacy, Biogen set the drug’s list price at $56,000 per year.Controversial Alzheimer’s drug could cost US $334B—nearly half of DoD budget
The new Alzheimer’s drug that could break MedicarePatients are desperate for hope. But there are serious concerns about Biogen’s new $56,000 treatment.The new Alzheimer’s drug that could break Medicare